Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Jingwen YuanColorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID 0000-0001-9554-0592
Zhiying PengColorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Rongbo WenColorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Leqi ZhouColorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Fuao CaoColorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Tianshuai ZhangColorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Yingjie WuColorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Jiayue WuColorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Ran LinColorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Guanyu YuColorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID 0000-0001-5416-3559
Wei ZhangColorectal Surgery Department, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID 0000-0003-3094-9711
Funding
Major National Science and Technology Project 2023ZD0500103National Natural Science Foundation of China 82272705National Natural Science Foundation of China 82473439National Natural Science Foundation of China 82503486Naval Medical University "Deep Blue" Project Talent Program, the First Affiliated Hospital of Naval Medical University Special Project for Basic Medical Research 2023PY04Naval Medical University "Deep Blue" Project Talent Program, the First Affiliated Hospital of Naval Medical University Special Project for Basic Medical Research 2023QD003Naval Medical University Project 2024QN028Shanghai "Rising Stars of Medical Talents" Youth Development Program of the Shanghai Mu-nicipal Health Commission 2024-70Shanghai Science and Technology Plan Project 25SF1901500Shanghai Shenkang Hospital Development Center, Shanghai Clinical Cohort Project SHDC2025CCS019the First Affiliated Hospital of Naval Medical University Special Project for Clinical Research 2024LYA02the first batch of open research projects of Shanghai Key Laboratories 2025QN02the first batch of open research projects of Shanghai Key Laboratories 2025QN12
6 · The paper itself
Abstract
5-Fluorouracil (5-Fu) remains essential in colorectal cancer (CRC) treatment, but monotherapy causes severe toxicity and faces chemoresistance. Combination regimens are encouraged to improve efficacy and safety. Natural compounds like Baicalin show anti-tumor potential in other gastrointestinal cancers, yet their role in CRC, particularly in overcoming 5-Fu resistance, is underexplored. The combined effect of Baicalin and 5-Fu was evaluated through in vitro functional assays and an in vivo xenograft model. Mechanisms were investigated using Western blot, qPCR, and RNA-seq. Baicalin enhanced 5-Fu to inhibit CRC progression both in vitro and in vivo. Mechanistically, Baicalin enhanced 5-Fu cytotoxicity by activating the MLKL-dependent necroptosis pathway. This study proposes the Baicalin and 5-Fu combination as a novel and potent chemosensitizing strategy for CRC, especially in 5-Fu-resistant cases, and provides a mechanistic rationale for Baicalin as a chemotherapy-enhancing agent.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Baicalin Augments 5-Fluorouracil Efficacy in Colorectal Cancer by Triggering MLKL-Dependent Necroptosis: A Novel Strategy to Overcome Chemoresistance. · full record | OpenQuestion